drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
T cells from the patient’s previous stem-cell transplant donor engineered to express an anti-CD5 chimeric antigen receptor to target CD5 on malignant T cells and induce CAR T-cell cytotoxic activity with expected on-target depletion of normal CD5+ T cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic T cells from the patient’s prior stem-cell transplant donor are engineered to express an anti-CD5 chimeric antigen receptor. CAR engagement of CD5 on malignant T cells triggers CD3 zeta and costimulatory signaling, activating the T cells to kill targets via perforin/granzyme-mediated cytotoxicity and cytokine release, with expected on-target depletion of normal CD5+ T cells.
drug_name
Donor-derived CD5 CAR T cells (prior SCT donor)
nct_id_drug_ref
NCT06316856